A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms
Adenocarcinoma

Interventions

DRUG: JNJ-69086420
DRUG: JNJ-78278343
RADIATION: Stereotactic body radiation therapy

Sponsor

Janssen Research & Development, LLC